Βίο-ομοειδή: μπορούν να πραγματοποιήσουν τις υποσχέσεις τους;

Σπυρόπουλος, Αλέξανδρος

Can biosimilars live up to their promise?

Master Thesis

Author

Σπυρόπουλος, Αλέξανδρος

Date

2021-06

Abstract

Biosimilars are a class of drugs that are intended to used as a substitute for the original biological drugs. These drugs (biosimilars) may begin to be produced as soon as the patent that protected the original biological drug is no longer valid. From this time point, any company that is active in the field of drugs, may start the immediate production of biosimilar drugs without legally committing to obtaining approval from the company whose patent has expired. However, it is common for companies to produce the corresponding biosimilar drug. Also, the production cost of this class of drugs is substantially lower. This can happen as it is not necessary to spend financial recourses on research which is necessary for the development of original biopharmaceuticals. Data also presented concerning member states of the European Union in order to demonstrate whether it is possible to save money from the National Health System and thus ensure their sustainability. Additional data are presented concerning the United States of America and the Asian countries. Concerning the Asian countries, India has been chosen as the field of research. Finally, in this assignment are presented facts which directly concern the use of biosimilar drugs in the pandemic of Sars-Cov2 (Covid-19).

Postgraduate Studies Programme

Βιοοικονομία, Κυκλική Οικονομία και Βιώσιμη Ανάπτυξη

Department

Σχολή Οικονομικών, Επιχειρηματικών και Διεθνών Σπουδών. Τμήμα Οικονομικής Επιστήμης

Number of pages

Language

Greek

URI

https://dione.lib.unipi.gr/xmlui/handle/unipi/13699
http://dx.doi.org/10.26267/unipi_dione/1122

Collections

Τμήμα Οικονομικής Επιστήμης

Show full item record

Except where otherwise noted, this item's license is described as
Αναφορά Δημιουργού-Μη Εμπορική Χρήση-Όχι Παράγωγα Έργα 3.0 Ελλάδα